<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000922.v1.p1" parentStudy="phs000922.v1.p1" createDate="2015-05-28" modDate="2015-10-16">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Catherine Wu, MD</td><td>Dana-Farber Cancer Institute, Boston, MA, USA</td></tr>
		<tr><td>Funding Source</td><td>Grant U54 HG003067</td><td>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genetic Aberrations and Subclonal Structure Impact Chronic Lymphocytic Leukemia</StudyNameEntrez>
	<StudyNameReportPage>Genetic Aberrations and Subclonal Structure Impact Chronic Lymphocytic Leukemia</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Longitudinal</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Large-scale whole-exome sequencing (WES) of primary tumor samples enables the unbiased discovery of recurrent putative driver events and patterns of clonal evolution. We report the identification of 44 recurrently mutated genes and 11 recurrent CNVs through the WES of 538 chronic lymphocytic leukemia (CLL) and matched germline DNAs. These include previously unrecognized cancer drivers (e.g., RPS15, IKZF3), and collectively identify nuclear export, MYC activity and MAPK signaling as central pathways affected by somatic mutation in CLL. A clonality analysis of this large dataset further enabled the reconstruction of temporal relationships between these driver events. Several drivers were associated with shorter progression-free survival (PFS) in 280 samples that were collected prior to uniform treatment with front line chemo-immunotherapy, with mature follow up of greater than 10 years. Direct comparison between matched pretreatment and relapse CLL from 59 samples demonstrated marked clonal evolution occurring in more than 95% of these patients. Distinct patterns of clonal evolution in relationship to specific gene alteration were observed, suggesting a hierarchy of fitness amongst mutations. Thus, large WES datasets of clinically informative samples enables the discovery of novel driver genes as well as the network of relationships between the drivers and their impact on disease relapse and clinical outcome.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Dan A. Landau1,2,3,4*, Eugen Tausch5*, Amaro N. Taylor-Weiner1*,       Chip Stewart1, Johannes G. Reiter1,2,6,7, Jasmin Bahlo8, Sandra       Kluth8, Ivana Bozic7,9, Mike Lawrence1, Sebastian Bo ttcher10, Scott       L. Carter1,11, Kristian Cibulskis1, Daniel Mertens5,12, Carrie L.       Sougnez1, Mara Rosenberg1, Julian M. Hess1, Jennifer Edelmann5,       Sabrina Kless5, Michael Kneba10, Matthias Ritgen10, Anna Fink8,       Kirsten Fischer8, Stacey Gabriel1, Eric S. Lander1, Martin A.       Nowak7,9,13, Hartmut Do hner5, Michael Hallek8,141, Donna Neuberg151,       Gad Getz1,161, Stephan Stilgenbauer51 and Catherine J.Wu" title="Mutations driving CLL and their evolution in progression and       relapse" journal="Nature, 2015 Oct 22, 526:525-530"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Leukemia, Lymphocytic, Chronic, B-Cell"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Catherine Wu, MD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston, MA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Grant U54 HG003067</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CRM-MDS" longName="Disease-Specific (Cancer Research and Methods, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000922.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000922.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000922.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer Research and Methods, MDS)</ConsentName>
        <ConsentAbbrev>DS-CRM-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer Research and Methods.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
